Experts have raised a number of concerns about the the risks of using experimental, unregulated peptides
However, without appropriate nutritional guidance and support from healthcare professionals, there is a real risk that reduced food intake could compromise dietary quality, meaning people may not get enough protein, fibre, vitamins, and minerals essential for maintaining overall health. Access to Treatment and Gaps in Care Guidance from the National Institute for Health and Care Excellence (NICE) recommends semaglutide as a weight management option for people who meet specific criteria, including a body mass index (BMI) of at least 35.0 kg/m2 and comorbidity (that is, they also have other conditions such as type 2 diabetes, cardiovascular disease, etc)
Yes, other companies are developing oral versions of GLP-1 and dual-acting drugs, though most are still in clinical trials
4 Danish Pharmacovigilance Council, Danish Medicines Agency, Copenhagen, Denmark Correspondence: Reimar W Thomsen, Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Olof Palmes All 43-45, 8200 Aarhus N, Denmark, Email [email protected] Purpose: A surge in the use of semaglutide injection (Ozempic ) approved to treat type 2 diabetes (T2D) has led to a global supply shortage
Common formulations include: BPC-157: 10 mg per vial in typical KLOW formulations TB-500: 10 mg per vial in typical KLOW formulations GHK-Cu: 50 mg per vial in typical KLOW formulations (highest proportion) KPV: 10 mg per vial in typical KLOW formulations Total blend: 80 mg combined peptide content Individual component research dosing: BPC-157 studies: 10 mcg/kg most common in rat models (range: 1-1000 mcg/kg) TB-500 studies: 1-10 mg/kg typical range in rodent research GHK-Cu studies: 0.01-100 nanomolar in cell culture
The pull: why people still try it The marketing hits three buttons fast
